忘備録
Mifeprex REMS Study Group. (2017). Sixteen years of overregulation: Time to unburden Mifeprex. The New England Journal of Medicine, 376(8), 790–794. https://doi.org/10.1056/NEJMsb1612526
Abstract
This Sounding Board article argues against the need for the currently required Risk Evaluation and Mitigation Strategy (REMS) for the drug Mifeprex for abortion, given the very low rate of adverse events associated with its use.
PubMedでは以下の通り。DOIが同一である：
doi: 10.1056/NEJMsb1612526.
Sixteen Years of Overregulation: Time to Unburden Mifeprex
Mifeprex REMS Study Group; Elizabeth G Raymond 1, Kelly Blanchard 2, Paul D Blumenthal 3, Kelly Cleland 4, Angel M Foster 5, Marji Gold 6, Daniel Grossman 7, Mary K Pendergast 8, Carolyn L Westhoff 9, Beverly Winikoff 1
Affiliations Expand
PMID: 28225670 DOI: 10.1056/NEJMsb1612526
類似した論文：
Raymond, E., Chong, E., Winikoff, B., Platais, I., Mary, M., Lotarevich, T., ... & Priegue, E. 2019. TelAbortion: evaluation of a direct to patient telemedicine abortion service in the United States. Contraception, 100(3), 173-177.
https://ohsu.elsevierpure.com/en/publications/telabortion-evaluation-of-a-direct-to-patient-telemedicine-aborti（2025年3月31日アクセス）
Raymond, E. G., Grossman, D., Mark, A., Upadhyay, U. D., Dean, G., Creinin, M. D., Coplon, L., Perritt, J., Atrio, J. M., Taylor, D., & Gold, M. 2020. Commentary: No-test medication abortion: A sample protocol for increasing access during a pandemic and beyond. Contraception, 101(6), 361–366. https://doi.org/10.1016/j.contraception.2020.04.005. （2025年3月30日アクセス）
Rough, E. 2025. “Abortion in Northern Ireland: recent changes to the legal framework.” UK Parliament, House of Commons Library.
commonslibrary.parliament.ukダウンロード可
Erlank, C. P., Lord, J., & Church, K. 2021. Acceptability of no-test medical abortion provided via telemedicine during Covid-19: analysis of patient-reported outcomes. BMJ Sexual & Reproductive Health. https://doi.org/10.1136/bmjsrh-2020-200954
